Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joel G Turner

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Current Medicinal Chemistry|November 11, 2008
CRM1-mediated nuclear export of proteins and drug resistance in cancerJoel G Turner, Daniel M Sullivan
Biochemical Pharmacology|January 3, 2012
Nuclear export of proteins and drug resistance in cancerJoel G Turner, Jana Dawson, Daniel M Sullivan
Seminars in Cancer Biology|March 18, 2014
Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agentsJoel G Turner, Jana Dawson, Christopher L Cubitt, et al.
Journal of Cell Science|June 3, 2004
Human topoisomerase IIalpha nuclear export is mediated by two CRM-1-dependent nuclear export signalsJoel G Turner, Roxanne Engel, Jennifer A Derderian, et al.
Molecular Cancer Therapeutics|April 18, 2009
HDAC2 regulates chromatin plasticity and enhances DNA vulnerabilityDouglas C Marchion, Elona Bicaku, Joel G Turner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbetaDouglas C Marchion, Elona Bicaku, Joel G Turner, et al.
Cancer Research|August 20, 2009
Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibitionJoel G Turner, Douglas C Marchion, Jana L Dawson, et al.
Journal of Cancer|October 25, 2013
CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex VivoJoel G Turner, Jana Dawson, Michael F Emmons, et al.
Blood|August 3, 2013
Human regulatory T cells against minor histocompatibility antigens: ex vivo expansion for prevention of graft-versus-host diseaseAnandharaman Veerapathran, Joseph Pidala, Francisca Beato, et al.
Molecular Carcinogenesis|May 3, 2005
Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progressionAmy C Cook, Alan B Tuck, Susan McCarthy, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Current Medicinal Chemistry|November 11, 2008
CRM1-mediated nuclear export of proteins and drug resistance in cancerJoel G Turner, Daniel M Sullivan
Biochemical Pharmacology|January 3, 2012
Nuclear export of proteins and drug resistance in cancerJoel G Turner, Jana Dawson, Daniel M Sullivan
Seminars in Cancer Biology|March 18, 2014
Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agentsJoel G Turner, Jana Dawson, Christopher L Cubitt, et al.
Journal of Cell Science|June 3, 2004
Human topoisomerase IIalpha nuclear export is mediated by two CRM-1-dependent nuclear export signalsJoel G Turner, Roxanne Engel, Jennifer A Derderian, et al.
Molecular Cancer Therapeutics|April 18, 2009
HDAC2 regulates chromatin plasticity and enhances DNA vulnerabilityDouglas C Marchion, Elona Bicaku, Joel G Turner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbetaDouglas C Marchion, Elona Bicaku, Joel G Turner, et al.
Cancer Research|August 20, 2009
Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibitionJoel G Turner, Douglas C Marchion, Jana L Dawson, et al.
Journal of Cancer|October 25, 2013
CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex VivoJoel G Turner, Jana Dawson, Michael F Emmons, et al.
Blood|August 3, 2013
Human regulatory T cells against minor histocompatibility antigens: ex vivo expansion for prevention of graft-versus-host diseaseAnandharaman Veerapathran, Joseph Pidala, Francisca Beato, et al.
Molecular Carcinogenesis|May 3, 2005
Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progressionAmy C Cook, Alan B Tuck, Susan McCarthy, et al.
Pageof 2